Leerink Partnrs Weighs in on RCUS Q1 Earnings

Arcus Biosciences, Inc. (NYSE:RCUS) – Research analysts at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for shares of Arcus Biosciences in a report released on Wednesday, February 26th. Leerink Partnrs analyst D. Graybosch forecasts that the company will post earnings per share of ($0.55) for the quarter. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. Leerink Partnrs also issued estimates for Arcus Biosciences’ Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($0.11) EPS and FY2029 earnings at $0.79 EPS.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.17) by $0.14. The company had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%.

A number of other research firms have also recently commented on RCUS. Morgan Stanley decreased their price target on Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. Wedbush reiterated an “outperform” rating and issued a $36.00 target price on shares of Arcus Biosciences in a research note on Thursday, November 7th. HC Wainwright upgraded shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and upped their price target for the company from $18.00 to $24.00 in a research note on Wednesday. Finally, Bank of America lowered their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $30.25.

Arcus Biosciences Stock Down 0.8 %

Arcus Biosciences stock opened at $10.16 on Thursday. Arcus Biosciences has a 1-year low of $9.92 and a 1-year high of $20.31. The business has a fifty day moving average price of $13.57 and a 200-day moving average price of $15.46. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -3.22 and a beta of 0.84.

Insider Activity at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the business’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total transaction of $53,910.00. Following the sale, the chief financial officer now directly owns 60,138 shares in the company, valued at $902,070. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 12.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. R Squared Ltd purchased a new position in shares of Arcus Biosciences in the 4th quarter valued at about $26,000. Point72 Hong Kong Ltd acquired a new stake in Arcus Biosciences in the third quarter valued at approximately $47,000. Lazard Asset Management LLC lifted its stake in Arcus Biosciences by 3,321.3% in the fourth quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock worth $93,000 after acquiring an additional 6,078 shares during the last quarter. US Bancorp DE grew its holdings in Arcus Biosciences by 2,432.0% during the 4th quarter. US Bancorp DE now owns 6,887 shares of the company’s stock worth $103,000 after acquiring an additional 6,615 shares in the last quarter. Finally, Quest Partners LLC increased its position in shares of Arcus Biosciences by 40,904.3% in the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after purchasing an additional 9,408 shares during the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.